NEW YORK (360Dx) – VolitionRx on Tuesday announced a deal to evaluate and validate its technology and assist in the firm's efforts to secure large trials in cancer.

The three-year agreement is with Stefan Holdenrieder at the Institute of Laboratory Medicine of the German Heart Center at the Technical University of Munich. VolitionRx CEO Cameron Reynolds said in a statement that Holdenrieder will support the company’s analytical and preanalytical research and assist in its trials aimed at lung, pancreatic, prostate, colorectal, breast, and ovarian cancer.